List of Actoplus Met drug patents
Actoplus Met is owned by Takeda Pharms Usa.
Actoplus Met contains Metformin Hydrochloride; Pioglitazone Hydrochloride.
Actoplus Met has a total of 2 drug patents out of which 0 drug patents have expired.
Actoplus Met was authorised for market use on 29 August, 2005.
Actoplus Met is available in tablet;oral dosage forms.
The generics of Actoplus Met are possible to be released after 03 February, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101660 | TAKEDA PHARMS USA | Solid preparation |
Jan, 2027
(3 years from now) | |
| US9320714 | TAKEDA PHARMS USA | Tablet |
Feb, 2029
(5 years from now) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2005
Treatment: NA
Dosage: TABLET;ORAL
ACTOPLUS MET family patents
7
Japan
4
United States
2
Portugal
2
Spain
2
Korea, Republic of
2
Canada
2
New Zealand
2
European Union
1
Israel
1
South Africa
1
Denmark
1
Mexico
1
Australia
1
Hong Kong
1
Russia
1
Slovenia
1
Morocco
1
Norway
1
Costa Rica
1
Colombia
1
Brazil
1
Cyprus
1
Poland
1
China
1
Ukraine
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic